CFTR and cystic fibrosis: Currently, triple-combination elexacaftor-tezacaftor-ivacaftor (ETI) treatment has proved to be highly effective and safe when administered in clinical trials to patients with CF (pwCF), aged 2 years and older, harboring at least one F508del CFTR allele [3,4,5,6,7,8].